Dr. Feldman on Active Surveillance in Younger Men with Prostate Cancer

Adam Scott Feldman, MD, MPH
Published Online: Thursday, May 18, 2017



Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses a study focused on active surveillance in men with prostate cancer under the age of 60.

For men with low- to intermediate-risk prostate cancer, active surveillance is an option for attempting to avoid treatment. There is a study that focused on active surveillance in men under 60 years old. Historically, active surveillance has been avoided in younger men for the concern that they will eventually need treatment or harbor a more aggressive disease.

In this study, there were 432 men with a median age of 55 years. The median time of follow-up was 5.1 years.
 


Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses a study focused on active surveillance in men with prostate cancer under the age of 60.

For men with low- to intermediate-risk prostate cancer, active surveillance is an option for attempting to avoid treatment. There is a study that focused on active surveillance in men under 60 years old. Historically, active surveillance has been avoided in younger men for the concern that they will eventually need treatment or harbor a more aggressive disease.

In this study, there were 432 men with a median age of 55 years. The median time of follow-up was 5.1 years.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Genitourinary CancersJul 28, 20171.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
$emailPop$